Jennifer Eilemberg - DermTech Chief Officer
| DMTKDelisted Stock | USD 0.04 0.02 71.36% |
Insider
Jennifer Eilemberg is Chief Officer of DermTech
| Phone | 858 450 4222 |
| Web | https://www.dermtech.com |
DermTech Management Efficiency
The company has return on total asset (ROA) of (0.386) % which means that it has lost $0.386 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2175) %, meaning that it created substantial loss on money invested by shareholders. DermTech's management efficiency ratios could be used to measure how well DermTech manages its routine affairs as well as how well it operates its assets and liabilities.DermTech currently holds 54.39 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. DermTech has a current ratio of 11.95, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about DermTech's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| John Hendricks | Curiositystream | 73 | |
| Waleed MD | TransMedics Group | 57 | |
| Laura Damme | TransMedics Group | N/A | |
| Doreen Ng | Fulgent Genetics | N/A | |
| Nabeel Ahmed | Outset Medical | 49 | |
| Andre Silva | Curiositystream | N/A | |
| Danilo DAlessandro | Clearpoint Neuro | 40 | |
| Bakori Davis | Curiositystream | N/A | |
| Michael MD | Outset Medical | N/A | |
| Tonya Saffer | Outset Medical | N/A | |
| James Mazzola | Outset Medical | N/A | |
| Nicole Shannon | Outset Medical | N/A | |
| Martin Vazquez | Outset Medical | 53 | |
| Stacey Porter | Outset Medical | 48 | |
| Peter Westley | Curiositystream | 60 | |
| Lawrence MD | Fulgent Genetics | 68 | |
| DABMG FACMG | Fulgent Genetics | 55 | |
| John Carey | TransMedics Group | 59 | |
| Brandon Perthuis | Fulgent Genetics | N/A | |
| Tamer MD | TransMedics Group | 56 | |
| Rob Burk | Curiositystream | N/A | |
Management Performance
| Return On Equity | -1.22 | |||
| Return On Asset | -0.39 |
DermTech Leadership Team
Elected by the shareholders, the DermTech's board of directors comprises two types of representatives: DermTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DermTech. The board's role is to monitor DermTech's management team and ensure that shareholders' interests are well served. DermTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DermTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin MBA, Treasurer CFO | ||
| Burkhard MD, Chief Officer | ||
| Todd Wood, Chief Officer | ||
| Daniel Visage, Senior Access | ||
| Steven Stone, Senior Development | ||
| Loren MD, Chief Officer | ||
| JD Esq, General Counsel | ||
| Ray JD, G Counsel | ||
| Jennifer Eilemberg, Chief Officer | ||
| Ray Bassi, VP Sales | ||
| John MD, CEO Pres | ||
| William Zondler, Chief Officer | ||
| Steve Kunszabo, Director Relations | ||
| Michael Howell, Chief Officer | ||
| Bret Christensen, CEO President | ||
| Mark Aguillard, Chief Officer | ||
| Claudia Ibarra, Chief Officer |
DermTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DermTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.22 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (5.33) % | |||
| Current Valuation | 15.43 M | |||
| Shares Outstanding | 34.96 M | |||
| Shares Owned By Insiders | 2.62 % | |||
| Shares Owned By Institutions | 18.09 % | |||
| Number Of Shares Shorted | 3.36 M | |||
| Price To Earning | (139.70) X | |||
| Price To Book | 0.02 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in DermTech Stock
If you are still planning to invest in DermTech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DermTech's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |